| Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer S Cedres, D Torrejon, A Martinez, P Martinez, A Navarro, E Zamora, ... Clinical and Translational Oncology 14, 864-869, 2012 | 351 | 2012 |
| Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non–small-cell lung cancer (NSCLC) S Cedrés, I Nuñez, M Longo, P Martinez, E Checa, D Torrejón, E Felip Clinical lung cancer 12 (3), 172-179, 2011 | 306 | 2011 |
| Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM) S Cedrés, S Ponce-Aix, J Zugazagoitia, I Sansano, A Enguita, ... PloS one 10 (3), e0121071, 2015 | 240 | 2015 |
| Tarlatamab for patients with previously treated small-cell lung cancer MJ Ahn, BC Cho, E Felip, I Korantzis, K Ohashi, M Majem, O Juan-Vidal, ... New England Journal of Medicine 389 (22), 2063-2075, 2023 | 109 | 2023 |
| Impact of BRAF mutation class on disease characteristics and clinical outcomes in BRAF-mutant lung cancer I Dagogo-Jack, P Martinez, BY Yeap, C Ambrogio, LA Ferris, C Lydon, ... Clinical Cancer Research 25 (1), 158-165, 2019 | 109 | 2019 |
| Fluorescence In Situ Hybridization and Immunohistochemistry as Diagnostic Methods for ALK Positive Non-Small Cell Lung Cancer Patients P Martinez, J Hernández-Losa, Ma Ángeles Montero, S Cedrés, ... PloS one 8 (1), e52261, 2013 | 85 | 2013 |
| Immunotherapy for the first-line treatment of patients with metastatic non–small cell lung cancer P Martinez, S Peters, T Stammers, JC Soria Clinical Cancer Research 25 (9), 2691-2698, 2019 | 83 | 2019 |
| Exploratory analysis of activation of PTEN–PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM) S Cedres, MA Montero, P Martinez, A Martinez, V Rodriguez-Freixinos, ... Lung cancer 77 (1), 192-198, 2012 | 76 | 2012 |
| Personalizing therapy with targeted agents in non-small cell lung cancer R Dienstmann, P Martinez, E Felip Oncotarget 2 (3), 165, 2011 | 74 | 2011 |
| Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors PA Jänne, RB Cohen, AD Laird, S Macé, JA Engelman, R Ruiz-Soto, ... Journal of Thoracic Oncology 9 (3), 316-323, 2014 | 56 | 2014 |
| Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer C Rolfo, E Giovannetti, P Martinez, S McCue, A Naing NPJ Precision Oncology 7 (1), 26, 2023 | 48 | 2023 |
| Targeted therapy as an alternative to whole-brain radiotherapy in egfr-mutant or alk-positive non–small-cell lung cancer with brain metastases P Martínez, RH Mak, GR Oxnard JAMA oncology 3 (9), 1274-1275, 2017 | 44 | 2017 |
| Durvalumab activity in previously treated patients who stopped durvalumab without disease progression S Sheth, C Gao, N Mueller, P Martinez, JC Soria Annals of Oncology 30, v475-v476, 2019 | 34 | 2019 |
| Cabazitaxel versus topotecan in patients with small-cell lung cancer with progressive disease during or after first-line platinum-based chemotherapy TL Evans, BC Cho, K Udud, JR Fischer, FA Shepherd, P Martinez, ... Journal of Thoracic Oncology 10 (8), 1221-1228, 2015 | 34 | 2015 |
| A phase I safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor XL765 (SAR245409) in combination with erlotinib (E) in patients (pts) with advanced solid tumors. RB Cohen, PA Janne, JA Engelman, P Martínez, Y Nishida, S Gendreau, ... Journal of Clinical Oncology 28 (15_suppl), 3015-3015, 2010 | 28 | 2010 |
| Phase I study of MEDI3726: a prostate-specific membrane antigen-targeted antibody–drug conjugate, in patients with mCRPC after failure of abiraterone or enzalutamide JS de Bono, MT Fleming, JS Wang, R Cathomas, MS Miralles, J Bothos, ... Clinical Cancer Research 27 (13), 3602-3609, 2021 | 27 | 2021 |
| Concordance of PD-L1 expression by different immunohistochemistry (IHC) definitions and in situ hybridization (ISH) in squamous cell carcinoma (SCC) of the lung. A Martinez Marti, P Martinez, A Navarro, S Cedres, N Murtra-Garrell, ... Journal of Clinical Oncology 32 (15_suppl), 7569-7569, 2014 | 27 | 2014 |
| Expression of Wilms’ tumor gene (WT1) is associated with survival in malignant pleural mesothelioma S Cedrés, MA Montero, E Zamora, A Martínez, P Martínez, L Fariñas, ... Clinical and Translational Oncology 16, 776-782, 2014 | 25 | 2014 |
| A Phase IB, dose-finding study of erlotinib in combination with a fixed dose of pertuzumab in patients with advanced non–small-cell lung cancer E Felip, M Ranson, S Cedrés, E Dean, M Brewster, P Martínez, V McNally, ... Clinical lung cancer 13 (6), 432-441, 2012 | 25 | 2012 |
| A phase 1b study to evaluate the safety and efficacy of durvalumab in combination with tremelimumab or danvatirsen in patients with relapsed or refractory diffuse large B-cell … V Ribrag, ST Lee, D Rizzieri, MJS Dyer, L Fayad, R Kurzrock, L Andritsos, ... Clinical Lymphoma Myeloma and Leukemia 21 (5), 309-317. e3, 2021 | 23 | 2021 |
Davis Torrejon CastroPhysician Scientist Medical Oncology在 mednet.ucla.edu 的电子邮件经过验证
